Richard Nash

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi request reprint Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors
    R A Nash
    Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, University of Washington, Seattle, WA, USA
    Blood 96:2062-8. 2000
  2. ncbi request reprint Effect of c-mpl ligands after total body irradiation (TBI) with and without allogeneic hematopoietic stem cell transplantation: low-dose TBI does not prevent sensitization
    Richard A Nash
    Biol Blood Marrow Transplant 8:360-7. 2002
  3. pmc High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis
    Richard A Nash
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 102:2364-72. 2003
  4. pmc Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 9:583-91. 2003
  5. pmc Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Arthritis Rheum 54:1982-6. 2006
  6. pmc High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 110:1388-96. 2007
  7. ncbi request reprint Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL
    R A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA
    Curr Opin Immunol 8:674-80. 1996
  8. pmc Immunomodulatory effects of mixed hematopoietic chimerism: immune tolerance in canine model of lung transplantation
    R A Nash
    Fred Hutchinson Cancer Research Center, bUniversity of Washington School of Medicine, Seattle, WA, USA
    Am J Transplant 9:1037-47. 2009
  9. pmc Early recovery of CD4 T cell receptor diversity after "lymphoablative" conditioning and autologous CD34 cell transplantation
    Jan Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington, USA
    Biol Blood Marrow Transplant 14:1373-9. 2008
  10. ncbi request reprint Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
    P A McSweeney
    Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA, USA
    Blood 97:3390-400. 2001

Detail Information

Publications72

  1. ncbi request reprint Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors
    R A Nash
    Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, University of Washington, Seattle, WA, USA
    Blood 96:2062-8. 2000
    ....
  2. ncbi request reprint Effect of c-mpl ligands after total body irradiation (TBI) with and without allogeneic hematopoietic stem cell transplantation: low-dose TBI does not prevent sensitization
    Richard A Nash
    Biol Blood Marrow Transplant 8:360-7. 2002
    ..The significant effect that rhTPO-specific antibodies had on the platelet counts may limit the clinical role of recombinant c-mpl ligands unless sensitization can be prevented...
  3. pmc High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis
    Richard A Nash
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 102:2364-72. 2003
    ..This was a heterogeneous high-risk group, and a phase 3 study is planned to fully assess efficacy...
  4. pmc Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 9:583-91. 2003
    ..The differences between equine and rabbit ATG are not yet clearly defined, and they should not be considered interchangeable in this regimen without further study...
  5. pmc Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Arthritis Rheum 54:1982-6. 2006
    ..To evaluate the safety and efficacy of allogeneic hematopoietic cell transplantation (HCT) after myeloablative conditioning in patients with severe systemic sclerosis (SSc)...
  6. pmc High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 110:1388-96. 2007
    ..Sustained responses including a decrease in dermal fibrosis were observed exceeding those previously reported with other therapies. HDIT and autologous HCT for SSc should be evaluated in a randomized clinical trial...
  7. ncbi request reprint Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL
    R A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA
    Curr Opin Immunol 8:674-80. 1996
    ....
  8. pmc Immunomodulatory effects of mixed hematopoietic chimerism: immune tolerance in canine model of lung transplantation
    R A Nash
    Fred Hutchinson Cancer Research Center, bUniversity of Washington School of Medicine, Seattle, WA, USA
    Am J Transplant 9:1037-47. 2009
    ..Establishing MC is immunomodulatory and observed changes were consistent with activation of both the effector and regulatory immune response...
  9. pmc Early recovery of CD4 T cell receptor diversity after "lymphoablative" conditioning and autologous CD34 cell transplantation
    Jan Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington, USA
    Biol Blood Marrow Transplant 14:1373-9. 2008
    ..Thus, the therapy may not be completely T cell lymphoablative...
  10. ncbi request reprint Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
    P A McSweeney
    Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA, USA
    Blood 97:3390-400. 2001
    ..Future protocol modifications should reduce rejection and GVHD, thereby facilitating studies of allogeneic immunotherapy for a variety of malignancies. (Blood. 2001;97:3390-3400)..
  11. ncbi request reprint Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation
    V Ratanatharathorn
    University of Michigan, Ann Arbor Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 92:2303-14. 1998
    ..The survival disadvantage in advanced disease patients receiving tacrolimus warrants further investigation...
  12. ncbi request reprint IL-2 does not enhance the conversion to complete donor chimerism following nonmyeloablative hematopoietic cell transplantation in dogs
    G E Georges
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Bone Marrow Transplant 31:1027-31. 2003
    ..These results show that IL-2 given with DLI after nonmyeloablative transplantation in dogs is not effective in reliably converting mixed to complete donor chimerism...
  13. ncbi request reprint Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection
    D Sangiolo
    Transplantation Biology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Gene Ther 14:1549-54. 2007
    ..The expression of IMPDH(IY) would allow in vivo selection with MMF, and DeltaCD34/TK expression would allow rapid and safe elimination of transduced T cells if graft-versus-host disease developed...
  14. ncbi request reprint Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial
    E Kansu
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Blood 98:3868-70. 2001
    ..76; 95% confidence interval, 0.48-1.21; P =.25). In addition, there were no significant differences between the 2 groups in transplantation-related mortality, survival, or disease-free survival...
  15. ncbi request reprint Purified canine CD34+Lin- marrow cells transduced with retroviral vectors give rise to long-term multi-lineage hematopoiesis
    B Bruno
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington Medical School, Seattle, USA
    Biol Blood Marrow Transplant 7:543-51. 2001
    ..Whereas canine CD34+Lin- marrow cells contributed to long-term multilineage hematopoiesis, progeny of CD34-Lin- progenitor cells were not detected after transplantation in these experiments...
  16. ncbi request reprint Molecular cloning and in vivo evaluation of canine granulocyte-macrophage colony-stimulating factor
    R A Nash
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98104
    Blood 78:930-7. 1991
    ..Evaluation of survival times of 51Cr-labeled autologous platelets suggested increased consumption as the primary reason for thrombocytopenia. A species-specific GM-CSF will be a useful tool for hematologic or immunologic studies in dogs...
  17. ncbi request reprint A proposed objective way to assess results of randomized prospective clinical trials with acute graft-versus-host disease as an outcome of interest
    H Al-Ghamdi
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
    Br J Haematol 113:461-9. 2001
    ..Further studies will be needed to determine if similar methods could be used in randomized clinical trials for prevention of GVHD...
  18. ncbi request reprint Assessment of myocardial hypertrophy by echocardiography in adult patients receiving tacrolimus or cyclosporine therapy for prevention of acute GVHD
    G Espino
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109-1024, USA
    Bone Marrow Transplant 28:1097-103. 2001
    ..The increase in LVMI after transplant in the cyclosporine group was greater than in the tacrolimus group but was not associated with any significant clinical events...
  19. ncbi request reprint Allogeneic HSCT for autoimmune diseases: conventional conditioning regimens
    R A Nash
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, Washington 98109 1024, USA
    Bone Marrow Transplant 32:S77-80. 2003
    ....
  20. ncbi request reprint Optimizing a canine survival model of orthotopic lung transplantation
    A S Farivar
    University of Washington Medical Center, Division of Cardiothoracic Surgery, Seattle, Washington 98195, USA
    Transplant Proc 38:1638-40. 2006
    ..Herein, we describe optimization of a canine survival model of orthotopic lung transplantation...
  21. ncbi request reprint Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation
    G E Georges
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, WA 98109 1024, USA
    Blood 95:3262-9. 2000
    ..We propose that mixed chimerism established after nonmyeloablative allogeneic stem-cell transplantation provides a platform for adoptive immunotherapy that has clinical potential in the treatment of patients with malignant diseases...
  22. ncbi request reprint Unrelated and HLA-nonidentical related donor marrow transplantation for thalassemia and leukemia. A combined report from the Seattle Marrow Transplant Team and the International Bone Marrow Transplant Registry
    K M Sullivan
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Ann N Y Acad Sci 850:312-24. 1998
    ..Using the paradigm of CML, it is likely that access to curative therapy of thalassemia will improve with optimal HLA typing and donor selection early in the course of disease...
  23. ncbi request reprint Polyclonal hematopoiesis with variable telomere shortening in human long-term allogeneic marrow graft recipients
    G Mathioudakis
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 96:3991-4. 2000
    ..These data suggest that under standard transplantation conditions, the stem cell proliferative potential is not compromised during hematopoietic reconstitution. (Blood. 2000;96:3991-3994)..
  24. ncbi request reprint Current and future preparative regimens for bone marrow transplantation in thalassemia
    R Storb
    Transplantation Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Ann N Y Acad Sci 850:276-87. 1998
    ..Mixed donor/host chimerism (> or = 50% donor cells in all lineages) has persisted for > 80 weeks, even though immunosuppression was discontinued after five weeks...
  25. ncbi request reprint Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting
    R Storb
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Ann N Y Acad Sci 872:372-5; discussion 375-6. 1999
    ..This paper describes the development of nonmyeloablative marrow transplant programs that have little toxicity in a canine model and their translation to patients with malignant and nonmalignant hematological diseases...
  26. ncbi request reprint Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st century
    M Maris
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle 98109-1024, USA
    Front Biosci 6:G13-6. 2001
    ....
  27. pmc Therapy with mycophenolate mofetil for refractory acute and chronic GVHD
    T Furlong
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Bone Marrow Transplant 44:739-48. 2009
    ..The area under the curve plasma concentrations of mycophenolic acid seemed to be suboptimal among patients with acute GVHD but not among those with chronic GVHD. MMF can be used effectively for treatment of GVHD...
  28. ncbi request reprint Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect
    L Feinstein
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, P O Box 19024, Seattle, Washington 98109 1024, USA
    Ann N Y Acad Sci 938:328-37; discussion 337-9. 2001
    ..Remissions occurred gradually over periods of weeks to a year. If long-term efficacy is demonstrated, such a strategy would expand treatment options for patients who would otherwise be excluded from conventional allografting...
  29. ncbi request reprint Engraftment of DLA-haploidentical marrow with ex vivo expanded, retrovirally transduced cytotoxic T lymphocytes
    G E Georges
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle 98109, USA
    Blood 98:3447-55. 2001
    ..These results show that ex vivo expanded, transduced T cells maintained in vivo function and enhanced marrow engraftment...
  30. ncbi request reprint Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation
    J Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA
    Blood 98:3505-12. 2001
    ..Patients who received transplants in adulthood have a clinically insignificant deficiency of de novo-generated CD4 T cells, suggesting that in these patients the posttransplantation thymic insufficiency may not be fully reversible...
  31. ncbi request reprint Survival of small bowel transplants in canine mixed hematopoietic chimeras: preliminary results
    M Y Yunusov
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98109, USA
    Transplant Proc 34:3366-7. 2002
  32. pmc Antagonistic and agonistic anti-canine CD28 monoclonal antibodies: tools for allogeneic transplantation
    Scott S Graves
    Transplantation Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Transplantation 91:833-40. 2011
    ..This is based on the premise that specifically blocking CD28 allows inhibitory signals through CTLA-4 to proceed, which furthermore suppresses T-cell function...
  33. pmc A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients
    Hong Li
    Department of Pharmacy, Box 357630, University of Washington, Seattle, WA 98195, USA
    J Clin Pharmacol 52:1654-64. 2012
    ..5, 3, 5, and 6 hours from the start of the infusion precisely estimated MPA AUC(0-12 h) for Q12-hour IV MMF. A comparable schedule (2, 2.5, 3, 4, and 6 hours) similarly estimated MPA AUC(0-8) (h) for Q8-hour dosing...
  34. pmc Identification and characterization of canine dendritic cells generated in vivo
    Marco Mielcarek
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 13:1286-93. 2007
    ..In summary, CD11c+/HLA-DR+/CD14-/DM5- cells obtained from canine peripheral blood have functional and morphologic characteristics similar to those of human myeloid DC...
  35. ncbi request reprint Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease
    A I Benito
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave, North, D1-100, P.O. Box 19204, Seattle, WA 98109-1204, USA
    Transplantation 72:1924-9. 2001
    ..CONCLUSION: These data suggest that sirolimus has activity in the treatment of steroid-refractory acute GVHD. However, there was considerable toxicity and further dose optimization studies seem warranted...
  36. ncbi request reprint Secondary failure of platelet recovery after hematopoietic stem cell transplantation
    B Bruno
    The Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington Medical School, Seattle 98109-1024, USA
    Biol Blood Marrow Transplant 7:154-62. 2001
    ..The identification of the characteristics and risk factors for SFPR could improve patient counseling and management and lead to the design of effective treatment strategies...
  37. ncbi request reprint Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study
    Dario Sangiolo
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:521-9. 2005
    ..Further studies are required to establish whether the drug has an etiologic role in these situations...
  38. ncbi request reprint Canine CD34: cloning of the cDNA and evaluation of an antiserum to recombinant protein
    P A McSweeney
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA
    Blood 88:1992-2003. 1996
    ....
  39. ncbi request reprint Molecular cloning of the CD3 epsilon subunit of the T-cell receptor/CD3 complex in dog
    R A Nash
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98104
    Immunogenetics 33:396-8. 1991
  40. ncbi request reprint Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 12:573-84. 2006
    ....
  41. ncbi request reprint Intussusception in canine recipients of hematopoietic cell grafts and surgical correction
    Murad Y Yunusov
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Comp Med 57:287-91. 2007
    ..Intussusception did not recur after surgical intervention in any dog. Recent HCT and post-transplant immunosuppressive therapy are not absolute contraindications to surgical intervention for intussusception in canine recipients of HCT...
  42. ncbi request reprint Pitfalls in the design of clinical trials for prevention or treatment of acute graft-versus-host disease
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 12:31-6. 2006
    ..Finally, investigators should be aware of regulatory and socioeconomic pitfalls that apply to all clinical trials...
  43. ncbi request reprint Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases--a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic an
    Linda M Griffith
    Biol Blood Marrow Transplant 12:688-90. 2006
  44. pmc Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors
    Terry Furlong
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA 98109 1024, USA
    Biol Blood Marrow Transplant 14:531-7. 2008
    ..In these studies, the addition of sirolimus to regimens containing a calcineurin inhibitor and methotrexate appeared to cause toxicity and provided no detectable improvement in preventing GVHD...
  45. ncbi request reprint Normal interleukin-7 (IL7) levels and normal IL7 response to CD4 T lymphopenia in patients with multiple sclerosis and systemic sclerosis
    Jan Storek
    Clin Immunol 121:118-9. 2006
  46. ncbi request reprint Partial donor-specific tolerance to delayed skin grafts after rejection of hematopoietic cell graft
    Murad Y Yunusov
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Transplantation 82:629-37. 2006
    ..DST may persist in recipients with transient mixed hematopoietic chimerism (MC) when solid organ transplantation and HCT are done concomitantly...
  47. ncbi request reprint Cyclophosphamide in scleroderma lung disease
    Keith M Sullivan
    N Engl J Med 355:1173-4; author reply 1174. 2006
  48. ncbi request reprint Autologous HSCT for advanced MS: is the glass half-empty or really half-full?
    Richard A Nash
    Brain 131:e89; author reply e90. 2008
  49. pmc Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d
    Chunkang Chang
    Department of Hematology, Shanghai Sixth People s Hospital, Shanghai Jiaotong University, Shanghai, People s Republic of China
    Blood 110:1379-87. 2007
    ..The data suggest that overall inferior outcome in patients with secondary MDS/tAML was related to the frequency of high-risk cytogenetics. For both cohorts, transplantation outcomes improved over the time interval studied...
  50. ncbi request reprint Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 1
    Linda M Griffith
    Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Biol Blood Marrow Transplant 11:862-70. 2005
  51. pmc Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation
    Luisa Giaccone
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 106:4381-8. 2005
    ..We conclude that increased MPA Css's predicted higher degrees of donor T-cell chimerism after unrelated donor nonmyeloablative HCT and suggest that targeting MPA Css's greater than 2.5 microg/mL could prevent graft rejection...
  52. ncbi request reprint Minor histocompatibility antigen-specific cytotoxic T lymphocytes generated with dendritic cells from DLA-identical littermates
    George E Georges
    Department of Medicine, University of Washington, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 9:234-42. 2003
    ..We conclude that after recent in vivo sensitization, large-scale ex vivo expansion of mHA-specific CTL was feasible using allogeneic DCs...
  53. ncbi request reprint FLT3 ligand promotes engraftment of allogeneic hematopoietic stem cells without significant graft-versus-host disease
    Murad Y Yunusov
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Transplantation 75:933-40. 2003
    ..It was hypothesized that the in vivo expansion of recipient dendritic cells (DC) with the administration of ligand for Flt3 (FL) could promote allogeneic engraftment after reduced-intensity conditioning by enhancing the GVH effect...
  54. ncbi request reprint NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors
    Ana I Benito
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D1 100, P O Box 19024, Seattle, WA 98109 1204, USA
    Leuk Res 27:425-36. 2003
    ..This model may allow identification of factors relevant for sustaining or expanding clonal precursors...
  55. ncbi request reprint High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation
    Timothy R McGuire
    Department of Pharmacy Practice, University of Nebraska Medical Center, 986045, Omaha, NE 68198 6045, USA
    Int Immunopharmacol 3:279-83. 2003
    ..In conclusion, in this small case series, there was no indication that CTX metabolism was different than that in other populations undergoing transplantation...
  56. ncbi request reprint Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality
    Manuel Jurado
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 8:161-9. 2002
    ..Future trials should explore the efficacy and tolerability of reduced-intensity conditioning regimens...
  57. pmc High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes
    Peter A McSweeney
    University of Colorado Health Sciences Center, Denver 80262, USA
    Blood 100:1602-10. 2002
    ..Responses in skin and mHAQ-DI scores exceed those reported with other therapies, suggesting that HDIT is a promising new therapy for SSc that should be evaluated in prospective randomized studies...
  58. ncbi request reprint Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone
    Sibel Koc
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 100:48-51. 2002
    ....
  59. ncbi request reprint High-dose immunosuppression and hematopoietic stem cell transplantation in autoimmune disease: clinical review
    Harry Openshaw
    City of Hope National Medical Center, Duarte, California 91010, USA
    Biol Blood Marrow Transplant 8:233-48. 2002
    ..Parallel trials in Europe and in the United States are in the late stages of design...
  60. ncbi request reprint Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease
    Terry Furlong
    Fred Hutchinson Cancer Research Center, and the Department of Medicine, University of Washington, Seattle 98109 1024, USA
    Biol Blood Marrow Transplant 8:206-12. 2002
    ..Fifty-three patients (51%) remain alive at 129-1883 days after transplantation. These results suggest that PUVA can be an effective therapy for steroid-resistant acute GVHD of the skin...
  61. ncbi request reprint Recombinant human macrophage colony-stimulating factor-induced thrombocytopenia in dogs
    Kraig Abrams
    Puget Sound Blood Center, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109 1024, USA
    Br J Haematol 121:614-22. 2003
    ..18; n = 4). These results support the concept that rhM-CSF induces an activation of the monocyte-macrophage system (MMS), which causes a reversible TCP in a dog model...
  62. ncbi request reprint Adoptive immunotherapy to increase the level of donor hematopoietic chimerism after nonmyeloablative marrow transplantation for severe canine hereditary hemolytic anemia
    Alessandra Takatu
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 9:674-82. 2003
    ..We conclude that DLI after nonmyeloablative HCT can increase the levels of donor cells contributing to hematopoiesis in recipients, inducing remissions of the hemolytic process and preventing complications associated with iron overload...
  63. ncbi request reprint A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:495-505. 2005
    ..Although a significant improvement in the prevention of GVHD was not suggested, compared with CSP and MTX, MMF in combination with CSP could be considered in cases in which MTX is contraindicated...
  64. pmc Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)
    Jan Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109 1024, USA
    Clin Immunol 113:285-98. 2004
    ..In conclusion, peripheral expansion of CD8 but not CD4 T cells is highly efficient. Prolonged CD4 lymphopenia is associated with relatively few infections, possibly due to antibodies produced by persisting pretransplant plasma cells...
  65. ncbi request reprint Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease
    Joseph H Antin
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 10:655-68. 2004
  66. ncbi request reprint Duration of immunosuppressive treatment for chronic graft-versus-host disease
    Betty L Stewart
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, PO Box 19024, Seattle, WA 98109, USA
    Blood 104:3501-6. 2004
    ..After the dose of prednisone was taken into account, progressive onset was not associated with an increased risk of nonrelapse mortality...
  67. ncbi request reprint Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 10:552-60. 2004
    ....
  68. ncbi request reprint Isolation and characterization of pediatric canine bone marrow CD34+ cells
    Steven E Suter
    Section of Medical Genetics, Department of Clinical Studies, University of Pennsylvania School of Veterinary Medicine, 3900 Delancey St, Philadelphia 19104, USA
    Vet Immunol Immunopathol 101:31-47. 2004
    ....
  69. ncbi request reprint Discordant functional and inflammatory parameters in multiple sclerosis patients after autologous haematopoietic stem cell transplantation
    Kathleen M Healey
    Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA
    Mult Scler 10:284-9. 2004
    ..The results demonstrate however, a dissociation of inflammation parameters and functional disability findings raising questions about optimal future stem cell transplantation strategies for this disease...
  70. ncbi request reprint Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 10:320-7. 2004
    ..A high diagnostic sensitivity and increased awareness that gut GVHD can occur without skin involvement account for the increased incidence of acute GVHD at our center...
  71. ncbi request reprint Transplantation of X-linked severe combined immunodeficient dogs with CD34+ bone marrow cells
    Brian J Hartnett
    Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia 19104, USA
    Biol Blood Marrow Transplant 8:188-97. 2002
    ....
  72. ncbi request reprint Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions
    Olaf Stuve
    Neurology Section, Medical Service, Veterans Affairs North Texas Health Care System, Dallas, TX, USA
    Arch Neurol 64:169-76. 2007
    ..Because it is currently impossible to identify patients at risk, and thus to prevent PML as a consequence of natalizumab therapy, it is important that neurologists be aware of possible therapeutic interventions...

Research Grants13

  1. Lung Transplantation and Immune Tolerance in Young Recipients
    Richard Nash; Fiscal Year: 2007
    ..Development of preclinical strategies for the induction of lung-specific tolerance in large animal models to prevent acute and chronic rejection will increase the probability of successful translation to human studies. ..
  2. Protection from GVHD with Gene-Modified Donor T Cells
    Richard Nash; Fiscal Year: 2007
    ....
  3. Nonmyeloablative Hematopoietic Cell Transplantation for Severe Systemic Sclerosis
    Richard Nash; Fiscal Year: 2006
    ..The unique observations in this study regarding responses and recovery of organs after inducing a sustained remission of SSc will serve to focus and direct other non-transplant research activities. ..
  4. HEMATOPOIETIC GROWTH FACTORS IN A CANINE STEM CELL MODEL
    Richard Nash; Fiscal Year: 2003
    ....
  5. ENGRAFTING SENSITIZED HOSTS WITH NONABLATIVE REGIMENS
    Richard Nash; Fiscal Year: 2002
    ..By lessening the morbidity and mortality associated with conventional conditioning, these studies could significantly change the management of selected inherited red blood cell diseases. ..